|
 |
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print March 19, 2008
J. Lipid Res., doi:10.1194/jlr.M800027-JLR200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Internal Medicine and Molecular Genetics, UT Southwestern Medical Center, Dallas, TX 75390-9046
Corresponding Author: jay.horton{at}utsouthwestern.edu
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that regulates the expression of low density lipoprotein receptor (LDLR) protein. Gain-of-function mutations in PCSK9 cause hypercholesterolemia and loss-of-function mutations result in lower plasma LDL-cholesterol. Here, we investigate the kinetics and metabolism of circulating PCSK9 relative to tissue levels of LDLRs. The administration of recombinant human PCSK9 (32 µg) to mice by a single injection reduced hepatic LDLRs by ~90% within 30 min and the receptor levels returned to normal within 6 h. The half-life of the PCSK9 was estimated to be ~5 min. Continuous infusion of PCSK9 (32 µg/h) into wild-type mice caused a ~90% reduction in hepatic LDLRs within 2 h and no associated change in the level of LDLR in the adrenals. Parallel studies were performed using a catalytically inactive form of PCSK9(S386A) and similar results were obtained. Infusion of PCSK9(D374Y), a gain-of-function mutation, resulted in accelerated clearance of the mutant PCSK9 and a greater reduction in hepatic LDLRs. Combined, these data suggest that exogenously administrated PCSK9 in plasma preferentially reduces LDLR protein levels in liver at concentrations found in human plasma and that PCSK9’s action on the LDLR is not dependent on catalytic activity in vivo.
Revised on February 27, 2008
Accepted on March 18, 2008
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. C. Chan, G. Lambert, P. H. R. Barrett, K.-A. Rye, E. M.M. Ooi, and G. F. Watts Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism? Clin. Chem., November 1, 2009; 55(11): 2049 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Poirier, G. Mayer, V. Poupon, P. S. McPherson, R. Desjardins, K. Ly, M.-C. Asselin, R. Day, F. J. Duclos, M. Witmer, et al. Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation: EVIDENCE FOR AN INTRACELLULAR ROUTE J. Biol. Chem., October 16, 2009; 284(42): 28856 - 28864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Luo, L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice J. Lipid Res., August 1, 2009; 50(8): 1581 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Lakoski, T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs Genetic and Metabolic Determinants of Plasma PCSK9 Levels J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2537 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Y. Chan, D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. From the Cover: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates PNAS, June 16, 2009; 106(24): 9820 - 9825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. McNutt, H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells J. Biol. Chem., April 17, 2009; 284(16): 10561 - 10570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Horton, J. C. Cohen, and H. H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J. Lipid Res., April 1, 2009; 50(Supplement): S172 - S177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Persson, C. Galman, B. Angelin, and M. Rudling Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors Endocrinology, March 1, 2009; 150(3): 1140 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Bottomley, A. Cirillo, L. Orsatti, L. Ruggeri, T. S. Fisher, J. C. Santoro, R. T. Cummings, R. M. Cubbon, P. Lo Surdo, A. Calzetta, et al. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants J. Biol. Chem., January 9, 2009; 284(2): 1313 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mayer, S. Poirier, and N. G. Seidah Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels J. Biol. Chem., November 14, 2008; 283(46): 31791 - 31801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Frank-Kamenetsky, A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates PNAS, August 19, 2008; 105(33): 11915 - 11920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Peterson, L. G. Fong, and S. G. Young Errata. PCSK9 function and physiology J. Lipid Res., July 1, 2008; 49(7): 1595 - 1599. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |